BioSpace News Archive

Medical Microinstruments, Inc. (MMI) , a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced it has raised $75 million in Series B financing.

BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round.

Bausch + Lomb Corporation announced Joseph C. Papa has stepped down as chair of the Board of Directors of the Company (the “Board”).

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the second quarter ended July 1, 2022 on Wednesday, August 10, 2022 after the market close.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced an upcoming presentation on DecisionDx®-Melanoma, the Company’s risk stratification gene expression profile (GEP) test, at the 2022 American Academy of Dermatology (AAD) Innovation Academy, being held in Vancouver, Canada, July 21-24.

This funding will be used to support KaloCyte as it scales up in advance of human trials.

Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market.

ReGelTec, Inc., announced that Dr. Douglas Beall won the award for Best Abstract at the American Society for Pain and Neuroscience annual meeting that just concluded in Miami, FL.

Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company’s second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET.

Auron Therapeutics, a biopharmaceutical company focused on developing therapies that target dysregulated differentiation and cellular plasticity for treating cancer, announced the completion of its $48 million Series A financing round.